Loading...

PE anti-mouse TCR γ/δ Antibody

Pricing & Availability
Clone
GL3 (See other available formats)
Regulatory Status
RUO
Other Names
T cell receptor γ/δ
Isotype
Armenian Hamster IgG
Ave. Rating
Submit a Review
Product Citations
publications
1_GL3_PE_090208.jpg
C57BL/6 splenocytes stained with CD3 (145-2C11) APC and GL3 PE
  • 1_GL3_PE_090208.jpg
    C57BL/6 splenocytes stained with CD3 (145-2C11) APC and GL3 PE
  • 2_41_Mouse_Thymus_CD44_TCRgt
    Confocal image of C57BL/6 mouse thymus sample acquired using the IBEX method of highly multiplexed antibody-based imaging: CD44 (blue) in Cycle 4 and TCRγδ (yellow) in Cycle 5. Tissues were prepared using ~1% (vol/vol) formaldehyde and a detergent. Following fixation, samples are immersed in 30% (wt/vol) sucrose for cryoprotection. Images are courtesy of Drs. Andrea J. Radtke and Ronald N. Germain of the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).
Compare all formats See PE spectral data
Cat # Size Price Save
118107 25 µg ¥11,930
118108 100 µg ¥22,580
Description

T cell receptor (TCR) is a heterodimer consisting of an α and a β chain (TCR α/β) or a γ and a δ chain (TCR γ/δ). TCR γ/δ belongs to the immunoglobulin superfamily, which is involved in the recognition of certain bacterial and tumor antigens bound to MHC class I. γ/δ TCR associates with CD3 and is expressed on a T cell subset found in the thymus, the intestinal epithelium, and the peripheral lymphoid tissues and peritoneum. Most γ/δ T cells are CD4-/CD8- although some are CD8+. T cells expressing the γ/δ TCR have been shown to play a role in oral tolerance, tumor-associated tolerance, and autoimmune disease. It has been reported that γ/δ T cells also play a principal role in antigen presentation.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Armenian Hamster
Immunogen
C57BL/6J intraepithelial lymphocytes
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

SB - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

The GL3 antibody has been shown to be useful in identifying γ/δ T cells by flow cytometry and immunohistochemistry and depleting γ/δ T cells in vivo. Additional reported applications (for the relevant formats) include: immunoprecipitation1, immunohistochemistry of acetone-fixed frozen sections2,6, and in vivo depletion of γ/δ T cells3-5.

Additional Product Notes

Iterative Bleaching Extended multi-pleXity (IBEX) is a fluorescent imaging technique capable of highly-multiplexed spatial analysis. The method relies on cyclical bleaching of panels of fluorescent antibodies in order to image and analyze many markers over multiple cycles of staining, imaging, and, bleaching. It is a community-developed open-access method developed by the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).

Application References

(PubMed link indicates BioLegend citation)
  1. Goodman T, et al. 1989. J. Exp. Med. 170:1569. (FC, IP)
  2. Cardona AE, et al. 2003. Infect. Immun. 71:2634. (IHC)
  3. Kapp JA, et al. 2004. Immunology 111:155. (Deplete)
  4. Skelsey ME, et al. 2001. J. Immunol. 166:4327. (Deplete)
  5. Ke Y, et al. 1997. J. Immunol. 158:3610. (Deplete)
  6. Podd BS, et al. 2006. J. Immunol. 176:6532. (IHC)
  7. Kasten KR, et al. 2010. Infect. Immun. 78:4714. (FC) PubMed
  8. Stadanlick JE, et al. 2011. J. Immunol. 187:664. PubMed
  9. Van Belle AB, et al. 2012. J. Immunol. 188:462. PubMed
Product Citations
  1. Polese B, et al. 2021. Cell Reports. 36(4):109456. PubMed
  2. Grigsby SM, et al. 2021. Cancers (Basel). 13:. PubMed
  3. Hutter K, et al. 2022. Front Immunol. 13:967914. PubMed
  4. Glaubitz J, et al. 2023. Gut. :. PubMed
  5. Teymournejad O, et al. 2023. NPJ Vaccines. 8:3. PubMed
  6. Mackel JJ, et al. 2022. Front Cell Infect Microbiol. 12:974175. PubMed
  7. Qiu Z, et al. 2022. J Exp Med. 219:. PubMed
  8. Naito Y, et al. 2019. American Journal of Physiology-Renal Physiology. 318(1):F238-F247. PubMed
  9. Pan Y, et al. 2021. Front Cell Neurosci. 15:664312. PubMed
  10. Akilov O, et al. 2009. J Immunol. 183:7994. PubMed
  11. Böttcher JP, et al. 2018. Cell. 172:1022. PubMed
  12. Michel M, et al. 2012. Proc Natl Acad Sci U S A. 109:17459. PubMed
  13. Shibata K, et al. 2014. J Immunol. 192:2210. PubMed
  14. Mathews J, et al. 2014. PLoS One. 9:97707. PubMed
  15. Schiller M, et al. 2021. Immunity. 54(5):1022-1036.e8. PubMed
  16. Liu X, et al. 2021. eLife. 0.416666666666667. PubMed
  17. Aldrich AL, et al. 2021. The Journal of Immunology. 206(4):751-765. PubMed
  18. Korangath P, et al. 2020. Bio Protoc. 10:e3822. PubMed
  19. Hutter K, et al. 2020. FEBS J. . PubMed
  20. Hanasoge Somasundara AV, et al. 2021. Cell Rep. 37:110099. PubMed
  21. Yang C, et al. 2021. J Invest Dermatol. 810:141. PubMed
  22. Liu S, et al. 2020. Cell Host & Microbe. 26(6):779-794.e8.. PubMed
  23. Moon S, et al. 2021. J Exp Med. 218:. PubMed
  24. Dai R, et al. 2021. Front Immunol. 12:727046. PubMed
  25. Jandke A, et al. 2020. Nat Commun. 3.075694444. PubMed
  26. Enomoto D, et al. 2017. PLoS One.. 10.1371/journal.pone.0183584. PubMed
  27. Xi‐Zhi J Guo et al. 2018. Immunity. 49(3):531-544 . PubMed
  28. Yang BH, et al. 2020. Cell Reports. 27(12):3629-3645.e6.. PubMed
  29. Chen W, et al. 2018. Biomed Res Int. 2018:5647120. PubMed
  30. Hobbs BE, et al. 2021. Pathogens. 10:. PubMed
  31. Rouse MD, et al. 2020. Front Microbiol. 11:414. PubMed
  32. Fujimoto M, et al. 2022. Nat Commun. 13:5408. PubMed
  33. Kong XF, et al. 2018. Nat Immunol. 19:973. PubMed
  34. Zhang H et al. 2019. Cell Rep. 29(2):391-405 . PubMed
  35. Zhao Y, et al. 2020. Front Immunol. 2.572222222. PubMed
  36. Ryu S, et al. 2021. eLife. 0.416666666666667. PubMed
  37. Pender M, et al. 2012. Blood. 120:5085. PubMed
  38. Chen YL, et al. 2022. Front Neurosci. 16:876582. PubMed
  39. Gawish R, et al. 2022. Elife. 11:. PubMed
  40. Zheng QY, et al. 2020. FASEB J. 34:10590. PubMed
RRID
AB_313831 (BioLegend Cat. No. 118107)
AB_313831 (BioLegend Cat. No. 118108)

Antigen Details

Structure
Ig superfamily, associates with CD3 complex.
Distribution

T cell subset in thymus, intestinal epithelium, peripheral lymphoid tissues and peritoneum, most γ/δ T cells are CD4-/CD8-, some are CD8+.

Function
Antigen recognition; γ/δ T cells are thought to play a role in tolerance.
Ligand/Receptor
Some bacterial or tumor antigens bound to MHC class I.
Cell Type
Epithelial cells, T cells, Tregs
Biology Area
Adaptive Immunity, Immunology
Molecular Family
TCRs
Antigen References
  1. Skarstein K, et al. 1995. Immunology. 81:497.
  2. Harrison LC, et al. 1996. J Exp Med. 184:2167.
  3. Wildner G, et al. 1996. Eur J Immunol. 26:2140.
  4. Brandes M, et al. 2005. Science. 309:264.
Gene ID
110066 View all products for this Gene ID 110067 View all products for this Gene ID
UniProt
View information about TCR gamma/delta on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.
If an antibody clone has been previously successfully used in IBEX in one fluorescent format, will other antibody formats work as well?

It’s likely that other fluorophore conjugates to the same antibody clone will also be compatible with IBEX using the same sample fixation procedure. Ultimately a directly conjugated antibody’s utility in fluorescent imaging and IBEX may be specific to the sample and microscope being used in the experiment. Some antibody clone conjugates may perform better than others due to performance differences in non-specific binding, fluorophore brightness, and other biochemical properties unique to that conjugate.

Will antibodies my lab is already using for fluorescent or chromogenic IHC work in IBEX?

Fundamentally, IBEX as a technique that works much in the same way as single antibody panels or single marker IF/IHC. If you’re already successfully using an antibody clone on a sample of interest, it is likely that clone will have utility in IBEX. It is expected some optimization and testing of different antibody fluorophore conjugates will be required to find a suitable format; however, legacy microscopy techniques like chromogenic IHC on fixed or frozen tissue is an excellent place to start looking for useful antibodies.

Are other fluorophores compatible with IBEX?

Over 18 fluorescent formats have been screened for use in IBEX, however, it is likely that other fluorophores are able to be rapidly bleached in IBEX. If a fluorophore format is already suitable for your imaging platform it can be tested for compatibility in IBEX.

The same antibody works in one tissue type but not another. What is happening?

Differences in tissue properties may impact both the ability of an antibody to bind its target specifically and impact the ability of a specific fluorophore conjugate to overcome the background fluorescent signal in a given tissue. Secondary stains, as well as testing multiple fluorescent conjugates of the same clone, may help to troubleshoot challenging targets or tissues. Using a reference control tissue may also give confidence in the specificity of your staining.

How can I be sure the staining I’m seeing in my tissue is real?

In general, best practices for validating an antibody in traditional chromogenic or fluorescent IHC are applicable to IBEX. Please reference the Nature Methods review on antibody based multiplexed imaging for resources on validating antibodies for IBEX.

Go To Top Version: 2    Revision Date: 04/21/2022

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account